ArticleCureus2025
Alternative Criteria to Address Major Flaws of Common Evaluation Metrics for Dose Distributions Through Characterization of Stereotactic Irradiation Plans for Brain Metastases Using the High-Definition Dynamic Radiosurgery Platform.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose This study aimed to reveal major flaws in common evaluation metrics for dose distributions of stereotactic radiosurgery (SRS) for brain metastases (BMs) and to present alternative methods that are more objective and more relevant to treatment outcomes through characterization of dose distributions with volumetric-modulated arcs (VMA) by a simple optimization method using the High Definition Dynamic Radiosurgery (HDRS) platform (Elekta AB, Stockholm, Sweden). Materials and methods The subjects were 37 lesions with the gross tumor volume (GTV) ranging from 0.04 cc to 48.09 cc (median: 7.32 cc), which were treated as solitary lesions. The main constituents of the HDRS are the 5-mm leaf-width, 160-leaf collimator Agility
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.